Acy of bosutinib (SKI-606) in persistent phase Philadelphia chromosome-positive continual myeloid
Acy of bosutinib (SKI-606) in continual phase Philadelphia chromosome-positive chronic myeloid leukemia sufferers with resistance or intolerance to imatinib. Blood, 2011; 118: 45676 6. Berman E, Nicolaides M, Maki RG et al: Altered bone and mineral metabolic process in patients receiving imatinib mesylate. N Engl J Med, 2006; 354: 20063 7. Fitter S, Dewar AL, Kostakis P et al: Long-term imatinib therapy promotes bone formation in CML sufferers. Blood, 2008; 111: 25387 eight. Mariani S, Giona F, Basciani S et al: Low bone density and decreased inhibin-BFSH ratio in a boy treated with imatinib through puberty. Lancet, 2008; 372: 1112 9. Schmid H, J er B, Lohse J, Suttorp M: Longitudinal CK1 list development retardation in a prepupertal girl with continual myeloid leukemia on long-term imatinib treatment. Haematologica, 2009; 94: 11779 10. Kimoto T, Inoue M, Kawa K: Development deceleration inside a lady taken care of with imatinib. Int J Hematol, 2009; 89: 2512 eleven. Millot F, Baruchel A, Guilhot J et al: Imatinib is productive but includes a adverse effect on development in kids with previously untreated continual myelogenous leukaemia (CML) in early continual phase (CP): results of your French nationwide phase IV trial. (abstract) Blood, 2009; 114: 356 twelve. Dewar AL, Cambareri AC, Zannettino AC et al: Macrophage colony-stimulating aspect receptor c-fms is often a novel target of imatinib. Blood, 2005; 105: 31272 13. Knight B, Tirnitz-Parker JE, Olynyk JK: C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice. Gastroenterology, 2008; 135: 9699 14. Tibullo D, Barbagallo I, Giallongo C et al: Effects of second-generation tyrosine kinase inhibitors in direction of osteogenic differentiation of human mesenchymal cells of nutritious donors. Hematol Oncol, 2012; 30: 273 15. Puttini M, Coluccia AM, Boschelli F et al: In vitro and in vivo exercise of SKI606, a novel Src-Abl inhibitor, towards imatinib-resistant Bcr-Abl neoplastic cells. Cancer Res, 2006; 66: 113142 16. Quintas-Cardama A, Kantarjian H, CDK5 Formulation Cortes J: Flying below the radar: the brand new wave of BCR-ABL inhibitors. Nat Rev Drug Discov, 2007; six: 8348 17. Pfizer Laboratories. Pharmacology Toxicology NDA Critique and Evaluation. Foods and Drug Administration (FDA) Center for Drug Evaluation and Study. NDA 2011 ID: 203341 Obtainable from: URL: http:accessdata.fda.gov drugsatfda_docsnda2012203341Orig1s000PharmR.pdf 18. Tauer JT, K ig S, Hofbauer LC, Suttorp M: A rat model to predict alterations in bone development and metabolism in young children with CML on imatinib. Haematologica, 2011; 96: 28 (abstract) 19. Cortes JE, Kim DW, Kantarjian HM et al: Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: benefits through the BELA trial. J Clin Oncol, 2012; 30: 34862 twenty. Tibullo D, Giallongo C, La CP et al: Results of imatinib mesylate in osteoblastogenesis. Exp Hematol, 2009; 37: 4618 21. Id BH, Lagneaux L, Najar M, Piccart M et al: The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer, 2010; ten: 298 22. Vandyke K, Dewar AL, Diamond P et al: The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J Bone Miner Res, 2010; 25: 17590 23. O’Sullivan S, Lin JM, Watson M et al: The skeletal effects on the tyrosine kinase inhibitor nilotinib. Bone, 2011; 49: 2819 24. Tokunaga A, Oya T, Ishii Y et al: PDGF receptor beta is really a potent regulator of mesenchymal stromal.
